HIIFS
ITCI

Harel Insurance Investments & Financial Services’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,300
Closed -$76K – 522
2018
Q2 		$76K Buy
+4,300
New +$87.3K ﹤0.01% 269

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Harel Insurance Investments & Financial Services's ITCI Position: Q3 2018 in Review

Harel Insurance Investments & Financial Services sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2018, closing a stake of 4,300 shares — an estimated $76K sold.

Harel Insurance Investments & Financial Services first reported a position in ITCI in Q2 2018 and held it in 1 quarter. The position peaked at $76K in Q2 2018. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2018.

  • Harel Insurance Investments & Financial Services reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2018 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 4,300 Intra-Cellular Therapies Inc. shares in Q3 2018, an estimated $76K.
  • Harel Insurance Investments & Financial Services first reported a position in Intra-Cellular Therapies Inc. in Q2 2018 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Intra-Cellular Therapies Inc. position peaked at $76K in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2018.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q3 2018, filed 29 Oct 2018.